Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

a and information to the FDA. We have since provided some supporting data to the FDA, and are in the process of finalizing a complete response to be submitted as soon as practicable."

Linda L. Chang, Senior Vice President and Chief Financial Officer, commented, "In 2012 we set an aggressive goal of reducing our monthly cash usage to further optimize our government contracting biodefense business model. We successfully met this goal while securing additional funding of $7.5 million through a credit facility provided by GE Capital.  These achievements, along with our ongoing efforts, will continue to ensure we have the flexibility to capably manage our expenses and capital requirements in 2013."

Year-End 2012 Financial ResultsRevenueFor the year ended December 31, 2012, PharmAthene recognized revenue of $25.2 million, compared to $24.3 million in 2011. Revenue in 2012 was derived primarily from development contracts with the U.S. government for the Company's biodefense product candidates.

Revenue for the SparVax® program increased in 2012 to approximately $22.9 million, compared to $19.3 million in 2011. Revenue in 2012 was primarily attributable to the achievement of several contract milestones, including the completion of Final Drug Product manufacture, progress in the development of bioanalytical and analytical assays, and the execution of non-clinical studies.

Revenue for the rBChE bioscavenger program in 2012 was approximately $1.8 million, compared to $0.7 million in 2011, corresponding with significant technical progress achieved during the year. On July 31, 2012 the Department of Defense exercised a $2.5 million option to continue to fund the rBChE program under its 2011 fixed price contract.

Revenue for the Valortim® program in 2012 was $0.5 million, compared to $3.7 million in 2011 as a result of the completion of the 2007 NIAID contract for Valortim® in the first quart
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Today, at the American ... , James McGough , M.D., ... the Semel Institute for Neuroscience and Human Behavior and ... at the University of California Los Angeles (UCLA), and ... Adolescent Psychopharmacology and ADHD at UCLA, presented the results ...
(Date:5/20/2013)... -- Dr. Gerald Zon , noted scientist ... a new blog in conjunction with TriLink BioTechnologies. The ... on what,s trending in the field of nucleic acids. ... of research presented at conferences and meetings, reviews of ... (PhD Princeton University 1971) developed automated synthesis of DNA ...
(Date:5/20/2013)... York, NY (PRWEB) May 20, 2013 With ... Cleaning Products said that although bed bugs need to be ... process will not compromise a person's health. And so to ... guide how to get rid of bed bugs ... its non-pesticide bed bug spray it called Bed Bug Bully. ...
(Date:5/20/2013)... CHAPEL HILL, N.C. , May 20, 2013 ... pharmaceutical company focused on developing differentiated antibiotics to ... bacterial infections, today announced that it presented data ... 2013) in Philadelphia demonstrating ... versus levofloxacin in Cempra,s prior Phase 2 clinical ...
Breaking Biology Technology:Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2
... , , SAN ... today that their Chief Executive Officer, William P. Spencer and Chief ... 2009 RedChip New York Equities Conference being held in New York ... is scheduled for 2:05 p.m. Eastern time on Wednesday, September 30, ...
... ... ... iCardiac Technologies, Inc., a leader in advanced cardiac core lab services and QT analysis, ... III cardiac safety study. iCardiac will provide end-to-end study management, site logistics and ...
... Spherix Incorporated (Nasdaq: SPEX ), an innovator in biotechnology ... services to food, supplement, biotechnology and pharmaceutical companies, today announced that ... 2009, at 9:00 a.m. Eastern time, at the Bethesda Marriott Suites, ... The items of business are: , , , ...
Cached Biology Technology:Imagenetix, Inc. to Present at the 2009 RedChip New York Equities Conference 2Leading Biotechnology Company Awards Phase III Cardiac Safety Study to iCardiac 2Spherix Incorporated Announces Annual Shareholders Meeting Date 2Spherix Incorporated Announces Annual Shareholders Meeting Date 3
(Date:5/20/2013)... known as the lungs of the planet, inhales carbon dioxide ... air to grow parts that eventually fall to the ground ... rainfall. , Until recently people believed much of the ... up deep in the ocean. University of Washington research showed ... dioxide though left open the question of how that ...
(Date:5/20/2013)... Geology articles posted online ahead of print ... swath of geoscience subdisciplines, including minerals exploration, archaeology, ... studied include Siberia; the Sumatran subduction margin; the ... Mars; and the Southeastern U.S. Atlantic Margin. Brief ... plate tectonics;, 2. The clear fingerprint of ice ...
(Date:5/18/2013)... 18, 2013) Research presented today at Digestive Disease ... with findings about the impact of coffee on autoimmune ... While coffee consumption recently has been associated with reduced ... a few more cups of java each month also ... disease. Researchers at the Mayo Clinic, Rochester, MN, linked ...
Breaking Biology News(10 mins):Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11Coffee consumption associated with reduced risk of autoimmune liver disease 2
... 14, 2010) -- Driven by rapid global industrialization, finite ... alternative energy options, meeting the world,s energy challenge may ... in the ubiquitous industrial invention: the factory. ... (CAMM) -- the only center of its kind in ...
... University have received a 2-year, $5.3 million grant from ... warfighters in the event of exposure to infectious diseases ... colleagues at the Biodesign Institute have taken on a ... that can protect soldiers against an unknown pathogenand do ...
... 13 Developing renewable energy sources has never been ... potential in this field. They convert direct sunlight into ... is constantly advancing, developing technologies that can convert power ... breakthroughs in this area, the editors of Energy Express, ...
Cached Biology News:ASU receives 2-year, $5.3 million DARPA award to safeguard soldiers from infectious diseases 2Energy Express focus issue: Thin-film photovoltaic materials and devices 2Energy Express focus issue: Thin-film photovoltaic materials and devices 3
... Labsystems Wellmix is a high-quality four-place microplate ... The shaking speed is adjustable from 100 ... speed and a small orbit ensure effective ... time is quick and easy to set ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... System brings together two mature, well-understood ... capture surfaces. This combination produces a ... the detection of molecular binding events ... , Protein-specific capture molecules are immobilized ...
... a comprehensive experiment based analysis package designed ... yet sophisticated and powerful functionality., Image acquisition ... cameras for easy image capture. Sequential ... Video Playback Saturation Warning ...
Biology Products: